Pearl River Capital’s Nektar Therapeutics NKTR Stock Holding History

Pearl River Capital’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-3	Closed	-$2K	–	637
2018 Q4	$2K	Buy	+3	New	+$1.81K	0.01%	786

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Pearl River Capital's NKTR Position: Q1 2019 in Review

Pearl River Capital sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 3 shares — an estimated $2K sold.

Pearl River Capital first reported a position in NKTR in Q4 2018 and held it in 1 quarter. The position peaked at $2K in Q4 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

Pearl River Capital reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
Pearl River Capital sold 3 Nektar Therapeutics shares in Q1 2019, an estimated $2K.
Pearl River Capital first reported a position in Nektar Therapeutics in Q4 2018 and held it in 1 quarter.
Pearl River Capital's Nektar Therapeutics position peaked at $2K in Q4 2018.
350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Pearl River Capital's 13F filing for Q1 2019, filed 2 May 2019.